101 citations
,
April 1994 in “Baillière's clinical endocrinology and metabolism” 5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.
235 citations
,
October 2004 in “The Journal of urology/The journal of urology” Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
223 citations
,
March 2011 in “The Journal of Sexual Medicine” Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.
90 citations
,
May 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
66 citations
,
September 2023 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
66 citations
,
April 2014 in “Journal of Dermatological Treatment” Finasteride and dutasteride effectively treat hair loss, but may cause side effects like sexual dysfunction and depression.
60 citations
,
December 1998 in “Clinical Pharmacology & Therapeutics” Both drugs lower DHT levels, with GI198745 being more effective.
54 citations
,
June 2018 in “International journal of risk & safety in medicine” Antidepressants, 5α-reductase inhibitors, and isotretinoin can cause long-lasting sexual dysfunction.
50 citations
,
March 2017 in “PeerJ” Using finasteride or dutasteride may cause long-lasting erectile dysfunction.
45 citations
,
March 2005 in “Steroids” Four new compounds were more effective than finasteride in treating prostate issues and hair loss, with one being 100 times more active and safe for use.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
32 citations
,
November 2017 in “Journal of Pharmaceutical Sciences” Chitosan-coated nanoparticles improve skin delivery of hair loss treatments with fewer side effects.
31 citations
,
January 2017 in “Advances in Experimental Medicine and Biology” Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.
31 citations
,
April 2008 in “International Journal of Andrology” 5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.
28 citations
,
August 2014 in “Cancer Causes & Control” Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.
28 citations
,
May 1986 in “Clinics in endocrinology and metabolism” New compounds may soon be tested to treat excessive hair growth in women.
22 citations
,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
22 citations
,
January 2001 in “Chemical & Pharmaceutical Bulletin” Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
20 citations
,
April 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
17 citations
,
August 2012 in “European journal of medicinal chemistry” New steroid compounds effectively inhibit 5α-reductase and may treat hair loss.
16 citations
,
August 2014 in “Archives of Pharmacal Research” Special nanoparticles increased skin absorption of hair loss treatments with fewer side effects.
13 citations
,
January 2017 in “Chemical & Pharmaceutical Bulletin” Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.
13 citations
,
October 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
12 citations
,
April 1995 in “Journal of Medicinal Chemistry” The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
10 citations
,
June 2010 in “Analytica Chimica Acta” New tests detect finasteride and dutasteride in urine quickly and easily.
8 citations
,
June 2020 in “The Journal of Clinical Endocrinology and Metabolism” Taking 5α-reductase inhibitors with prednisolone can worsen its negative effects on metabolism.
8 citations
,
June 1995 in “Helvetica Chimica Acta” Compound 15a was effective in inhibiting 5α-reductase.
8 citations
,
March 2002 in “Archiv Der Pharmazie” The compound 4c effectively inhibits the enzyme linked to hair loss.
3 citations
,
September 2017 in “Bioorganic & medicinal chemistry letters” New compounds were made that are promising for prostate cancer therapy.
3 citations
,
January 2001 in “Cambridge University Press eBooks” Finasteride effectively treats hair loss and enlarged prostate in men, with mild side effects.